MarginsXMarginsX
Home › Markets › Health Care › OCUL

Ocular Therapeutix Inc. (OCUL)

OCUL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.01
-3.22% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$52.0M
-18.5% on 2024
Net income · 2025
-$265.9M
-511.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/0001104659-26-010664-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerOCUL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001393434
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$52.0M
Net income-$265.9M
Operating income-$270.0M
Net margin-511.9%
Operating margin-519.8%
Revenue growth-18.5%
Cash$737.1M
Total assets$808.1M
P/E (computed)Net income was not positive
P/S (computed)25.5×

Warning signs

Cash runway
25.2 months
$530.6M cash at September 30, 2026
Share count, 1 year
+3.3%
2025-10-31 to 2026-11-06 · +177.0% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$3.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$530.6M cash; operating cash flow -$63.3M a quarter.Report 2026-09-30
Shares outstanding220,022,840 (2026-11-06); 213,047,472 a year earlier; 79,418,626 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-02-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $461K, sold $3.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$12.9M-$94.8M-$65.6M$530.6MNo debt tags$50.4M10-Q 2026-11-09
Q2 2026
2026-06-30
$13.5M-$78.8M-$67.3M$598.6MNo debt tags$52.1M10-Q 2026-08-03
Q1 2026
2026-03-31
$10.8M-$88.6M-$66.0M$666.7MNo debt tags$52.0M10-Q 2026-05-05
Q4 2025
2025-12-31
$13.3M-$64.7M-$54.2M$737.1MNo debt tags$52.0M10-K 2026-02-05
Q3 2025
2025-09-30
$14.5M-$69.4M-$50.7M$344.8MNo debt tags$55.8M10-Q 2026-11-09
Q2 2025
2025-06-30
$13.5M-$67.8M-$55.2M$391.1MNo debt tags$56.7M10-Q 2026-08-03
Q1 2025
2025-03-31
$10.7M-$64.1M-$44.7M$349.7MNo debt tags$59.6M10-Q 2026-05-05
Q4 2024
2024-12-31
$17.1M-$48.4M-$39.4M$392.1MNo debt tags$63.7M10-K 2026-02-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-09-30
Latest annual report10-K2026-02-05
Latest quarterly / interim10-Q2026-11-09
Latest current report
FORM 8-K
8-K2026-11-09
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 872 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.8%
1 month-14.2%
3 months-38.5%
Year to date-48.8%
1 year-44.5%
From 52-week high-61.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
INVAInnoviva Inc.$18.49-2.84%$1.3B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
MLYSMineralys Therapeutics Inc.$14.53-5.22%$1.3B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
GHRSGH Research PLC$18.75-1.83%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier